<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01483911</url>
  </required_header>
  <id_info>
    <org_study_id>ALX-0171-1.1/11</org_study_id>
    <nct_id>NCT01483911</nct_id>
  </id_info>
  <brief_title>ALX-0171 Phase I Study, Evaluating Single Ascending Dose and Multiple Dose in Healthy Male Volunteers</brief_title>
  <official_title>Phase I, Single-centre, Randomised, Placebo-controlled, Double-blinded Study, With Single Ascending Dose and Multiple Dose at Maximum Tolerated Dose, Evaluating the Safety, Tolerability and Pharmacokinetics of ALX-0171, Administered by Pulmonary Inhalation, in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ablynx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ablynx</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      ALX-0171 is a Nanobody directed against the human respiratory syncytial virus (RSV). The
      purpose of this first-in-man study is to determine the safety, tolerability and
      pharmacokinetics (PK) of ALX-0171 after single and multiple pulmonary administrations in
      healthy male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of treatment-emergent adverse events</measure>
    <time_frame>until 1 month after last study drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>plasma concentration of ALX-0171</measure>
    <time_frame>from predose until 5 days after study drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>RSV Infection</condition>
  <arm_group>
    <arm_group_label>ALX-0171</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALX-0171</intervention_name>
    <description>Single or multiple ascending doses (2.1-210 mg), administered via pulmonary inhalation. Multiple dosing will consist of twice daily dosing on 5 consecutive days.</description>
    <arm_group_label>ALX-0171</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single or multiple doses, administered via pulmonary inhalation. Multiple dosing will consist of twice daily dosing on 5 consecutive days.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-smoking healthy male volunteers, aged 18-55 years

          -  Good health condition, as determined by medical history, physical examination and
             clinical laboratory testing

          -  Forced expiratory volume in 1 second (FEV1) ≥ 90% of predicted value

          -  Diffusing capacity of the lung for CO (DLCO) ≥ 85% of predicted value

          -  Normal chest X-Ray (anteroposterior and lateral view)

          -  Minimum weight of 70.0 kg, minimum height of 1m70, body mass index between 18.0 and
             30.0 kg/m²

        Exclusion Criteria:

          -  Current smokers, or ex-smokers abstinent from tobacco for less than one year

          -  History or presence of atopy or pulmonary non-specific hyperreactivity

          -  Positive bronchial challenge test

          -  Symptomatic viral infection, or suspicion thereof (including rhinitis) in last 14 days
             prior to dosing

          -  Signs of active pulmonary infection or other inflammatory conditions, even in the
             absence of febrile episodes, in the last 14 days prior to dosing
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Josefin-Beate Holz, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ablynx</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2011</study_first_submitted>
  <study_first_submitted_qc>November 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2011</study_first_posted>
  <last_update_submitted>February 26, 2013</last_update_submitted>
  <last_update_submitted_qc>February 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

